Replies to post #196270 on Biotech Values
Moreover, I don’t think the V-Pak label change will materially alter ABBV’s exclusive contract with ESRX. ABBV would have a strong legal case, IMO, if ESRX tried to change the terms of the contract other than to ensure that V-Pak isn’t given to patients where it’s now contraindicated.
10/22/15 9:44 PM
10/27/15 5:06 PM
10/28/15 8:41 AM
10/30/15 2:50 PM
11/13/15 1:30 PM
11/18/15 6:07 PM
11/20/15 9:35 AM
11/23/15 5:56 PM
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |